Legal and ethical aspects

HTCR-Services is the sole service provider for the Human Tissue and Cell Research (HTCR) Foundation.

Legal and ethical aspects are essential in the collection and use of human tissues and clinical data. HTCR-Services is the exclusive service provider for the Human Tissue and Cell Research (HTCR) Foundation, which provides one of the highest ethical frameworks for working with human tissues and related samples. HTCR Foundation is a private non-profit initiative for the fair and timely access to these invaluable resources for both pharmaceutical industry and medical research community. Its framework regulates the informed written patient consent, data protection and anonymization as well as user application process for exclusion of non-ethical usage of human tissue (see

New users of human tissues and derivatives need to apply to the HTCR Foundation. HTCR Foundation’s independent scientific board examines the proposed study. Upon the approval by HTCR, the new users can obtain human biospecimens and related information through HTCR-Services.


    Our collaborating BioBanks maintain human tissue repositories of more than 40,000 samples from 4,000 donors. Tissue samples from over 600 consented donors are collected annually, mostly with oncological Read more

    We collect human tissues and/or the biological fluids from the same donor to meet the research requirements of our customers. The samples and/or cells can be provided freshly-collected or in multiple preserved formats according customer specifications.... read more
  • Our Portfolio

    Download and overview:  Portfolio

    Moving drugs from bench to bedside involves extensive characterization for safety and efficacy in pre-clinical studies using human-based cellular systems and animal models. However inadequate representation of the human tissue environment in pre-clinical models results in poorly validated therapeutic targets and inaccurate predictions of the drug candidate’s effects on humans. Resulting typically in high failure rate in clinical trials... read more